Health limitations, distance, work schedules, family obligations, and financial constraints are all barriers that prevent patients from participating in clinical trials. For those living with Long COVID, debilitating symptoms can make traveling to a study site impossible.
Now, Harlan Krumholz, M.D., Harold H. Hines, Jr. Professor of Medicine (Cardiology), is pioneering a new approach that makes participation in clinical research accessible for those whose lives have been upended by the post-acute infection syndrome. At Yale School of Medicine, working closely with Sterling Professor Akiko Iwasaki, Ph.D., he is the principal investigator of the Yale Paxlovid for Long COVID (PAX LC) Trial. This phase 2 investigational new drug clinical trial evaluating the use of the antiviral for people with Long COVID with a decentralized nationwide design that brings the research into participants’ homes. Operating throughout the contiguous United States, it is the first fully decentralized phase 2 trial with this complexity and scale.
Krumholz believes that this trial demonstrates that a future of clinical research that allows patients to participate at their convenience is not only possible, but more efficient and even cost-effective than standard clinical trials…
Read the full article here.
